Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference

Rhea-AI Summary

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the B. Riley Securities' Neuroscience Conference on April 28-29, 2021. Chairman and CEO Raj Mehra, Ph.D., will present on April 28 at 11:00am ET. The conference will address critical topics in neurodegeneration, neuropsychiatry, and mental health, featuring various healthcare companies. Seelos focuses on developing therapies for CNS disorders and rare diseases, boasting a portfolio that includes clinical assets for Acute Suicidal Ideation and Behavior (ASIB), ALS, and Parkinson's disease.

NEW YORK, April 15, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities' Neuroscience Conference, April 28-29, 2021.

Raj Mehra, Ph.D., Chairman and CEO, will present on Wednesday, April 28th at 11:00am ET. 

The B. Riley Securities' Neuroscience Conference will cover key topics across neurodegeneration, neuropsychiatry, and mental health disease areas, with both public and private healthcare companies. For more information about the conference: https://brileyfin.com/events

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com  
https://seelostherapeutics.com/  
https://twitter.com/seelostx  
https://www.linkedin.com/company/seelos

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference-301269110.html

SOURCE Seelos Therapeutics, Inc.

FAQ

What is the date of the B. Riley Securities Neuroscience Conference SEEL will attend?

The B. Riley Securities Neuroscience Conference will take place on April 28-29, 2021.

Who will represent Seelos Therapeutics at the Neuroscience Conference?

Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics, will present at the conference.

What topics will be covered at the B. Riley Securities Neuroscience Conference?

The conference will cover topics related to neurodegeneration, neuropsychiatry, and mental health.

What are Seelos Therapeutics' main focuses in their research?

Seelos Therapeutics focuses on developing therapies for CNS disorders and rare diseases.

When is Raj Mehra's presentation scheduled at the conference?

Raj Mehra's presentation is scheduled for April 28, 2021, at 11:00am ET.